Mealey's (October 24, 2018, 1:29 PM EDT) -- WASHINGTON, D.C. — In an Oct. 24 ruling, the Federal Circuit U.S. Court of Appeals agreed with the Patent Trial and Appeal Board that a patent application covering the controlled release of fumarates does not adequately disclose a method of treating multiple sclerosis (MS) with 480 mg of fumarates per day and, thus, suffers from an inadequate written description (FWP IP ApS v. Biogen MA Inc., No. 2017-2109, Fed. Cir.)....